Head-to-head · Cost-Efficiency Index
Neuvé Health vs Factor Health MD
Two GLP-1 programs on the bench, scored on the same six factors. Here's how their real cost of ownership compares — and which one we'd start with.
Neuvé Health
Readers who want the route and the base chosen explicitly and will ask what the monthly figure covers before enrolling.
Visit Neuvé HealthFactor Health MD
Those willing to commit to a 12-month term to capture the lowest headline price, since flexible month-to-month is nearly double.
Visit Factor Health MDThe verdict
Neuvé Health takes it, leading the Cost-Efficiency Index 68 to 67. Neuvé Health prices twelve GLP-1 products openly — injectable and sublingual, standard and low dose, with a B12 or a glycine base — and then says three different things about whether the medication is inside the monthly figure. Factor Health MD still earns a C — Those willing to commit to a 12-month term to capture the lowest headline price, since flexible month-to-month is nearly double.
Worth knowing either way: our overall #1 pick is CoreAge Rx (Cost-Efficiency Index 94/100 — the top of the ranking). See how it stacks up: CoreAge Rx vs Neuvé Health.
Factor by factor
Both providers scored on our six Cost-Efficiency Index factors. The stronger side on each row is marked in teal.
Normalized Cost/Month
Price Transparency
Nationwide Access
Formulation Options
Clinical Oversight
Contract Flexibility
Pricing, coverage & formulary
The disclosed facts behind the scores. Lower price wins its row (teal).
| Spec | Neuvé Health | Factor Health MD |
|---|---|---|
| Cost-Efficiency Index | 68/100 | 67/100 |
| Semaglutide / mo | $217/month (standard injectable with B12; the site gives three different answers on whether the medication is inside the figure) | $99/mo (all doses, annual plan, compounded) |
| Tirzepatide / mo | $324/month (standard injectable with B12; same unresolved question about what the figure covers) | $149/mo (all doses, annual plan, compounded) |
| Semaglutide / yr (modeled) | $2,604 | $1,188 |
| Tirzepatide / yr (modeled) | $3,888 | $1,788 |
| Coverage | All 50 states | Coverage not published |
| Oral / sublingual | Yes | No |
| Brand-name access | Compounded only | Compounded only |
| Rank here | #127 | #134 |
Neuvé Health
68/100Where the value is
- Prices twelve distinct GLP-1 products before any account: injectable and sublingual, standard and low dose, with a B12 or a B12-free glycine base for each
- States the 503A and 503B compounding classes on the homepage and the About page, which the August record did not find
- Names its founder as a nurse practitioner with a care role rather than referring only to an anonymous network
The tradeoffs
- Three surfaces disagree on whether the medication is inside the monthly price: the weight-loss page is headed "All-in monthly pricing" and lists the compounded drug as included, while its own fine print and the financial policy say medication, labs and supplies are billed separately
- The clinical partner that would settle that question — and that bills for the medication, the labs and the consultation — is never named
Factor Health MD
67/100Where the value is
- Every plan includes ALL doses at one flat rate with no per-mg escalation, confirmed explicitly in its own FAQ
- LegitScript certified (badge displayed in the site footer)
- Genuinely no long-term contract required for the flexible monthly tier, per its own FAQ
The tradeoffs
- The widely advertised 'From $99/mo' headline (used in the site's own page title) only applies to the 12-month prepaid Annual plan — the real no-commitment month-to-month price is $189/mo for semaglutide and $289/mo for tirzepatide, 91-94% higher
- No compounding pharmacy is individually named, only a generic 'network of licensed, FDA-regulated pharmacies'
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Cost-Efficiency Index. Pricing, states and verification reflect each provider's public disclosures at last review; prices change — confirm on the provider's site. Not medical advice. See our disclosure.